Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
A case report published in Oncotarget details a 38-year-old woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma shortly after receiving her second Pfizer-BioNTech mRNA vaccine dose, prompting calls for further investigation into potential immune-related mechanisms.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02452099 |
Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation. |
COMPLETED | NA |
| NCT01031641 |
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing |
COMPLETED | |
| NCT00796562 |
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy |
COMPLETED | PHASE2 |
| NCT00743028 |
Assess the Oral Bioavailability of New ABT-263 Formulations |
COMPLETED | PHASE1 |
| NCT00664677 |
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia |
TERMINATED | PHASE1 |
| NCT00380653 |
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes |
COMPLETED | PHASE1 |
